NASDAQ · SGRY

Surgery Partners, Inc.

$15.17 -$0.56 (-3.56%) 1D After hours

Key Metrics

$2.06B
Market cap
P/E · TTM
Revenue · TTM
−$76.10M
Net income
EPS · TTM $-0.60
Dividend yield
Free cash flow $208.00M
Beta · 1Y 0.89
EBITDA · TTM $571.60M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Mar 27
    From its Feb 18 high, the share price fell 28%.

    Peak close $15.99 on Feb 18; trough close $11.49 on Mar 27. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -28%
  • Mar 3
    The stock moved -12.3% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 3

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$2.06B
Enterprise value$5.59B
Shares outstanding130.8M
52-wk range$11.41 – $24.10
Avg volume · 20D898.8K
Net cash −$3.53B
Book value / share$13.33
IndustryServices-General Medical & Surgical Hospitals, Nec
ExchangeNASDAQ
About Surgery Partners, Inc.
IPO dateOct 1, 2015
Employees16000

Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF9.89
EV/EBITDA9.78
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC -4.4% · —

Financial Health

Current ratio1.86
Quick ratio1.69
Debt / equity2.20
Debt / EBITDA 6.50
Net cash −$3.53B
Working capital$500.80M

Cash Flow · TTM

Operating CF $280.00M
Capex −$72.00M
Free cash flow $208.00M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

4 / 9
Middling fundamentals · 4 of 9 signals passing

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings